Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PREP | P48147 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8994558 | 0.88 | MEN1 (0.56) | MEN1NPC1RAB9AKMT2APREP | |
| SCHEMBL13763519 | 0.88 | MEN1 (0.56) | MEN1NPC1RAB9AKMT2APREP | |
| SCHEMBL5742769 | 0.87 | ACE (0.60) | MEN1NPC1RAB9AKMT2APREP | |
| SCHEMBL5742774 | 0.87 | ACE (0.60) | MEN1NPC1RAB9AKMT2APREP | |
| SCHEMBL12883872 | 0.84 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2APREP | |
| SCHEMBL9476280 | 0.83 | FKBP1A (0.58) | FKBP1A | |
| SCHEMBL10510787 | 0.83 | ACE (0.58) | MEN1NPC1RAB9AKMT2AFKBP1A | |
| SCHEMBL5741652 | 0.83 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7330019 | 0.83 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5741647 | 0.83 | MEN1 (0.63) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | MEN1 191/4885NPC1 3089/4885RAB9A 1554/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | MEN1 191/4885NPC1 3089/4885RAB9A 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.